Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SURVEY 3 articles
October 9, 2006
- Taiyo Pharm. Completes Seamless Production Line for Prefilled Syringes
October 2, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 2, 2006
- Wholesalers Must Offer Well-Grounded Prices: Korosho Hearing
October 2, 2006
- Novartis, Daiichi Sankyo to Terminate Agreement for Lamisil AT, Nicotinel TTS
October 2, 2006
- Inter-ministerial Efforts Accelerated to Promote Life Science
October 2, 2006
- SSP to Launch CHOLESTEGUARD to Fight High Cholesterol
October 2, 2006
- Barcode Labering Requirements Annouced
October 2, 2006
- Industry Seeks to Bring About Gov't-Industry Dialogue: JPMA Policy Seminar
October 2, 2006
- New Head of PFSB Outlines Bureau's Plans at Press Conference
October 2, 2006
- REGULATORY NEWS IN BRIEF
October 2, 2006
- IMMD Completes PI Clinical Trial of IMD-0354
October 2, 2006
- Zydus Enters Generics Market in Japan
October 2, 2006
- 1st Drug Evaluation Forum to Be Held in January for Better Understanding between Industry and PMDA
October 2, 2006
- SELF-MEDICATION NEWS IN BRIEF
October 2, 2006
- R&D NEWS IN BRIEF
October 2, 2006
- More Companies Adopting New Method for Training MRs
October 2, 2006
- NEW PRODUCTS
October 2, 2006
- MREAC to Introduce New Seminar for MR Trainers
October 2, 2006
- Agilent Technology Launches New Compact LC/MS System, Highest Performance Q-TOF
October 2, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…